Signature Cytokines and Immune-Mediated Inflammatory Diseases The ability to block
specific cytokine pathways has revealed pathophysiological differences among autoimmune …

Interleukin-23 (IL-23) is a pro-inflammatory cytokine composed of two subunits, IL-23A (p19)
and IL-12/23B (p40), the latter shared with Interleukin-12 (IL-12). IL-23 is mainly produced …

Monoclonal antibodies (mAbs) have become one of the most important classes of
biopharmaceutical products, and they continue to dominate the universe of …

Background & Aims Guselkumab, a selective p19 interleukin-23 antagonist, is approved for
the treatment of plaque psoriasis and psoriatic arthritis. This study evaluated the efficacy and …

Objective To evaluate the efficacy and safety of an oral selective tyrosine kinase 2 (TYK2)
inhibitor, deucravacitinib, in patients with active psoriatic arthritis (PsA). Methods In this …

Summary Background The interleukin-23 (IL-23)/T-helper 17 cell pathway is implicated in
psoriatic arthritis pathogenesis. Guselkumab, an IL-23 inhibitor that specifically binds the IL …

Interleukin-17 (IL-17) is an essential proinflammatory cytokine, which is mainly secreted by
the CD4+ helper T cells (Th17 cells) and subsets of innate lymphoid cells. IL-17A is …

Psoriatic arthritis (PsA) is part of a group of closely related clinical phenotypes ('psoriatic
disease') that is defined by shared molecular pathogenesis resulting in excessive …

Objective To evaluate risankizumab, a biological therapy that inhibits interleukin 23, in
patients with active psoriatic arthritis (PsA) who have responded inadequately or are …

Psoriasis is a common inflammatory skin disease with multiple comorbidities, including
psoriatic arthritis and coronary artery disease, that can severely impact an individual's …